HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New combo injection shows promise for tough head and neck cancers
Disease control CompletedThis study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone. 18 a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Shorter radiation may ease burden for older head and neck cancer patients
Symptom relief CompletedThis study tested a shorter radiation treatment schedule for head and neck cancer in people aged 70 and older. Instead of daily visits for 6-7 weeks, the goal was to reduce side effects and help patients complete treatment. The study enrolled 37 participants and looked at whether…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 15, 2026 19:06 UTC
-
Can we predict who benefits from nivolumab in head and neck cancer?
Knowledge-focused CompletedThis study looked at 50 people with recurrent or metastatic head and neck squamous cell carcinoma who were treated with nivolumab. Researchers analyzed tumor tissue and blood samples to find immune markers that might predict who responds best to the drug. The goal is to better se…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:57 UTC